Licensed Diabetes Drug Could Dramatically Increase Human Life Span


The fountain of youth might soon become a reality as scientists prepare the first human trial for an anti-aging pill. Passing the 120 -candlemilestone in excellent health may have once been exclusive to biblical characters or descendantsof Beren, but researchersthinkthat everyone could live to that age thanks to a cheapdrug, called metformin, which is already commercially available andcurrently used for the therapy of diabetes.

The clinical trial is called Targeting Ageing with Metformin( TAME) and it will investigate if the drug is capable of slow and/ or stopping degenerative diseases and heart conditions. The U.S. Food and Drug Administration has allowed for trials to take place in winter of 2016, and scientists are planning to recruit 3,000 people in their 70 s and 80 s who either have or are at risk of having major cancers. The trial will likely takefive toseven years.

Last year, a study of more than 180,000 people showed that diabetes patients being treated with metformin not only lived longer than other diabetic patients, but also lived longer than the healthy control sample. Tests onanimalshave also pointed out that the drug widens their lifespanandkeeps the whole body healthier.

“If the effects are the same in humen as they have been in animal surveys, it is feasible for people to live healthily into their 120 s, ” said, a figure that appears to be based on worms living 40 percent longer than their life expectancy when given the drug.

One of the effects of thedrugis makingour cells better oxygenated, which can improveour health. The mechanism behind the increased oxygenation is not exactly clear, but scientists are not astonished that the extra oxygen had a positive impact on our body.

If the ability of the drug to slow down degenerative conditions such as Alzheimers and Parkinsonsis confirmed, it could altogether change the style we fight these cancers. People on metformin could have a biological age decades younger than their actual age.

“If you target an aging process and you slow down aging then you slow down all the diseases and pathology of aging as well. Thats revolutionary. Thats never happened before, ” study adviser Professor Gordon Lithgow from the Buck Institute for Research on Aging in Californiasaidto the media.

“I have been doing research into aging for 25 years and the idea that we would be talking about clinical trial in humen for an anti-aging drug would have been guessed inconceivable, but there is every reason to believe its possible.

Read more:


Please enter your comment!
Please enter your name here